The treatment options of the new angiotensin II receptor blocker - azilsartan medoxomil in the therapy of hypertension in patients with metabolic disorders
One of the key pathogenic mechanisms of the arterial hypertension (AH) development in patients with metabolic syndrome is the activation of the renin-angiotensin-aldosterone system (RAAS). According to these advantages we need to use drugs inhibiting the RAAS in the treatment of AH patients. This ar...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IP Morozov P.V.
2014-12-01
|
| Series: | Системные гипертензии |
| Subjects: | |
| Online Access: | https://syst-hypertension.ru/2075-082X/article/viewFile/29058/pdf |